(© Mohammed - stock.adobe.com)
Some Ozempic-Style Drug Users Averaged Under 800 Calories Daily, Small Study Finds
In A Nutshell
- Three of 14 patients in a small English study averaged under 800 calories a day, with the lowest at 541.
- Typical intake was 58.5% of estimated needs, and most fell short on fiber and vitamin D despite plenty of protein.
- Researchers measured food intake, not blood levels, so the gaps are not diagnosed deficiencies.
- Many patients reported little medical or dietary follow-up, and no monitoring system matches what weight-loss surgery patients receive.
Losing the urge to eat sounds like the perfect side effect for anyone who has battled hunger for years. In a small study from England, though, one woman taking Mounjaro averaged just 541 calories a day, and two other patients also ate under 800.
Published in BMJ Nutrition, Prevention & Health, the research studied 14 adults at a single NHS family doctor’s practice in Northamptonshire. Twelve took Mounjaro (tirzepatide), and two took semaglutide, sold as Wegovy or Rybelsus. Both drugs curb appetite, a big reason they work for weight loss. Protein intake looked healthy, but fiber, vitamin D and iron often fell short of recommended levels.
Patients who have weight-loss surgery get nutrition screening and dietitian follow-up, the authors note, but no equivalent monitoring system exists for these drugs.
Weight-Loss Drug Patients Typically Ate Barely Over Half the Calories They Needed
Researchers invited all 97 patients at Brackley Medical Centre who had been prescribed one of these drugs within the previous year. Seventeen agreed, and 14 finished: 11 women and 3 men, ages 27 to 73. Ten paid for the drugs privately, while four received them through the NHS, Britain’s public health system, three of them with type 2 diabetes. Patients with eating disorders or other conditions likely to significantly affect intake were excluded.
Participants logged meals in a food-tracking app called myfood24 for one to 10 days, typically three, and the main analysis used each person’s first two days. Intake was compared with official UK nutrition targets. Phone interviews of about 20 minutes covered experiences on the medication, changes in eating and support received. The authors called the work a service evaluation meant to generate questions for larger studies, not to prove the drugs cause nutrient gaps.
Typical daily intake was 1,231 calories, 58.5% of estimated needs. Eight of 14 participants ate less than two-thirds of their estimated requirement, and intake ranged from 541 to 2,312 calories. Three averaged under 800, a level at which multiple vitamin and mineral deficiencies become likely, according to research the authors cite. UK guidance says meal-replacement diets of 800 to 1,200 calories should happen only with specialist support, using nutritionally complete products. All three were eating self-selected diets without equivalent oversight, though one was enrolled in a structured support program.
Most Participants on Weight-Loss Drugs Fell Short on Fiber and Vitamin D
Protein was the exception. Typical intake ran about one and a half times the recommended amount, and only one person fell short. Fiber was the biggest nutrient gap, with 12 of 14 participants below two-thirds of the target, followed by vitamin D at 11 of 14. Iron fell short for half of the group. Vitamin D was counted from food only, not sunlight, which also supplies it. Researchers measured food intake rather than blood levels, so the gaps do not confirm diagnosed deficiencies.
Eight participants fell short on at least three of six priority nutrients: fiber, iron, vitamin D, potassium, magnesium and protein. The woman eating 541 calories missed all six. Three others missed five, and all three averaged about 830 calories or fewer. One of them, at 677.5 calories, drew more than 84% of her energy from ultra-processed foods. Another participant, at 1,421 calories, still missed four nutrients, so eating a moderate amount does not guarantee good nutrition. Fruit and vegetable intake fell below the recommended 400 grams a day, about five servings, in six of those eight. Most described home cooking or health-conscious choices, yet still fell short because they were eating so little overall.
Many Weight-Loss Drug Patients Reported Little Medical or Dietary Follow-Up
Interviews added a human side. Two participants expressed “shock” at how little they were eating, something they had not realized until completing the food diary. Others described reduced “food noise,” the constant mental chatter about eating, and called the drug a “turning point” or “game changer,” citing less pain, easier movement and renewed hope. Still, some avoided social meals because of nausea, and others feared regaining weight if they stopped the drug.
Support, though, was thin. Only a handful of participants were in structured programs offering personalized diet guidance and access to the prescriber. Many described a lack of structured NHS follow-up, and inadequate medication reviews left side effects such as dizziness and low blood pressure unmanaged, so some turned to online peer groups.
A much larger earlier study of more than 461,000 adults newly prescribed similar drugs found that 92% had no dietitian contact in the six months before treatment, and deficiencies were more likely to be caught among those who did.
Fourteen patients cannot show how common very low eating is among all users, or whether the drugs caused the shortfalls. Because the volunteers were motivated and health-engaged, the authors add, the findings may, “if anything, underestimate nutritional risk.” A medication that can mute hunger needs someone checking what patients actually eat. A few days of food logging was enough to flag the problem in this group, and larger studies are needed to learn how widespread it is.
Disclaimer: This article is for general informational purposes only and is not medical advice. The study described is small and preliminary, and its findings should not be used to diagnose, treat or change any medication or eating plan. Anyone taking a weight-loss medication who has concerns about appetite, nutrition or side effects should speak with a doctor, pharmacist or registered dietitian.
Paper Notes
Limitations
With only 14 participants drawn from one practice in a relatively affluent part of Northamptonshire, the sample was small. Most were women, and most paid privately for their prescriptions, which limits how well the results apply to NHS-prescribed patients, younger adults and people in less affluent areas where nutritional risk may be greater. Volunteers willing to track their diets may differ in motivation from those who declined, and some patients reportedly stayed out for fear their medication would be withdrawn. Food records covered one to 10 days per person, with the main analysis limited to the first two, which may not reflect habitual eating, and the data were self-reported without blood tests or an accuracy check. No diet information from before treatment was collected, so the design cannot separate the effects of the drugs from earlier eating habits or other factors. The study was observational, and the authors state that no causal conclusions are intended.
Funding and Disclosures
No specific grant from a public, commercial or not-for-profit funder was declared, and the authors report no competing interests. They thank the myfood24 team for allowing use of the platform and the NNEdPro Global Institute for Food, Nutrition and Health for academic support and in-kind support through its BMJ NPH waiver program. The authors also report using ChatGPT only for minor language editing. The project was registered as a service evaluation at Brackley Medical Centre, no NHS Research Ethics Committee approval was required, and all participants gave informed consent.
Publication Details
Titled “Uncovering nutritional deficiencies and the adequacy of wrap-around care for patients on GLP-1 and dual GIP/GLP-1 receptor agonists,” the paper was written by Dhanush Ammineni and Milou Ottolini, who contributed equally, along with Sumantra Ray, Rajna Golubic and Ellen Fallows. Authors are affiliated with the University of Oxford Medical Sciences Division, the NNEdPro Global Institute for Food, Nutrition and Health, Ulster University, the Oxford Centre for Diabetes, Endocrinology and Metabolism, and Brackley Medical Centre. It was published as an open-access original research article in BMJ Nutrition, Prevention & Health on November 17, 2026, after external peer review. DOI: 10.1136/bmjnph-2026-001622. Citation: Ammineni D, Ottolini M, Ray S, et al. Uncovering nutritional deficiencies and the adequacy of wrap-around care for patients on GLP-1 and dual GIP/GLP-1 receptor agonists. BMJ Nutrition, Prevention & Health 2026;0. doi:10.1136/bmjnph-2026-001622.







